Dario's Data-Driven Digital Health Platform Delivers Significant and Sustainable Improvements in Blood Pressure: Findings Published in JMIR Cardio

Rhea-AI Summary

DarioHealth (NASDAQ: DRIO) announced a peer-reviewed JMIR Cardio study (Dec 4, 2025) showing that data-driven digital nudges from its platform were associated with sustained blood pressure (BP) improvements in real-world users.

Key findings: users with high BP saw a larger monthly systolic BP reduction after three months (B = –2.09; P < .001) versus propensity-matched controls (B = –1.06; P = .007); users with higher lifestyle activity achieved greater reduction (B = –5.27; P < .001). 59% of Dario clients use its cardio-metabolic suite.

Positive

• Systolic BP decline of B = –2.09 at three months versus baseline
• Control comparison showed smaller reduction (B = –1.06; P = .007)
• Greater benefit for active users: B = –5.27 in systolic BP
• Broad client reach: 59% of clients use cardio-metabolic suite

Negative

• None.

Insights

Clinical Digital Health Analyst

Peer‑reviewed real‑world data link Dario's data‑driven nudges to modest but statistically significant systolic BP reductions at three months.

Dario's publication in JMIR Cardio reports that users receiving platform nudges showed a greater monthly average systolic blood pressure decline (B = –2.09; P < .001) than a propensity‑matched control (B = –1.06; P = .007), with higher self‑reported activity associated with an even larger reduction (B = –5.27; P < .001). These figures describe an association between personalized digital messages and measured BP changes in real‑world users, and they frame the platform as an active intervention rather than passive monitoring.

The findings rely on observational, retrospective data and propensity matching rather than randomized assignment, so causal claims require caution. The reported effect sizes are statistically robust but modest in magnitude; clinical benefit depends on baseline risk, absolute BP values, and durability beyond the reported three months. The claim that 59% of clients use the cardio‑metabolic suite supports reach, but it does not quantify baseline severity or downstream cost savings; those economic assertions remain directional within the disclosed text.

Items to watch: replication in randomized settings, reported absolute BP levels and clinician‑verified outcomes, duration of effect beyond three months, and any published analyses linking BP shifts to measured healthcare utilization or costs. Expect additional clarity on clinical significance and economic impact when those concrete endpoints appear in future publications or client outcomes reports.

Peer-reviewed JMIR Cardio study demonstrates real-world clinical impact of data-driven digital nudges on hypertension outcomes

Data-driven engagement translates to lower health risks and downstream cost savings for Dario clients

Results highlight Dario's ability to deliver lasting impact and further cement the Company's position as a proven leader in evidence-based digital care   

NEW YORK, Dec. 4, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced publication of a new peer-reviewed study in JMIR Cardio demonstrating that data-driven nudges delivered via Dario's digital health platform are associated with significant and sustainable improvements in blood pressure ("BP") outcomes.

The study, titled "The Impact of Digital Intervention Messages Targeting Users With High Blood Pressure Events: Retrospective Real-World Study," analyzed real-world BP data from platform users whose health was tracked over time, comparing a cohort that received digital intervention messages to a propensity-matched control group.

According to the CDC, nearly 120 million people in the U.S. live with hypertension, a major public health challenge that has been identified as the leading preventable risk factor for premature death. 59% of Dario's clients today leverage its cardio-metabolic suite to support members in managing hypertension. 

Key findings were that among users with high BP (high-BP cohort), those receiving digital nudges experienced a statistically significant reduction in monthly average systolic blood pressure three months after the intervention (B = –2.09; P < .001), compared to a smaller reduction in the control group (B = –1.06; P = .007).  Users reporting higher lifestyle activity levels further achieved greater systolic blood pressure reduction (B = –5.27; P < .001), underscoring the additive benefit of behavioral engagement in conjunction with digital nudges.

This research provides important real-world clinical evidence that personalized, data-driven digital interventions can meaningfully reduce blood pressure in individuals with hypertension – and help maintain healthy BP levels in individuals without overt hypertension. The fact that BP improvements persisted over time after the initial intervention shows that digital nudges via Dario's platform are not merely momentary triggers, but instead can support sustained, long-term management of hypertension.

"This new study represents strong clinical evidence that data-driven digital nudges – when delivered reliably via a robust platform – can move the needle on key cardiovascular health outcomes," said Dr. Omar Manejwala, Chief Medical Officer at Dario. "Indeed, for employers, payers and health systems evaluating digital health , BP control and long-term sustainability are critical – and we believe that these data show Dario's approach delivers both."

"The findings reinforce Dario's belief that personalized, behavior-informed digital interventions – not just passive monitoring – are essential to achieving meaningful clinical impact," added Yifat Hershcovitz, PhD, Vice President of Clinical & Scientific Affairs at DarioHealth.

For employers and healthcare clients, this translates into measurable value: by improving BP control across populations, digital health platforms like Dario have the potential to reduce downstream cardiovascular risks, lower costs associated with complications and improve overall population health – all while integrating seamlessly with existing care workflows.

About DarioHealth Corp. (NASDAQ: DRIO)

DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.

Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com. 

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the future benefits and value of the Company's platform for employers, payers and health systems, including the potential to reduce downstream cardiovascular risks and lower costs associated with complications and improve overall population health. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contacts

Michael Lipari
SVP Corporate Development
irteam@dariohealth.com
+1-201-785-6310

Rob Halpern
SVP Marketing
irteam@dariohealth.com 

Logo - http://mma.prnewswire.com/media/544126/DarioHealth_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/darios-data-driven-digital-health-platform-delivers-significant-and-sustainable-improvements-in-blood-pressure-findings-published-in-jmir-cardio-302632263.html

SOURCE DarioHealth Corp.

FAQ

What did the JMIR Cardio study published Dec 4, 2025 report about DarioHealth (DRIO) and blood pressure?

The study found Dario's data-driven nudges were associated with sustained systolic BP reductions (B = –2.09; P < .001) at three months versus baseline.

How did DarioHealth's digital nudges compare to a control group in the DRIO study?

The propensity-matched control group showed a smaller systolic reduction (B = –1.06; P = .007) compared with the nudged cohort.

Did activity level affect blood pressure outcomes in the DarioHealth (DRIO) study?

Yes; users reporting higher lifestyle activity had larger systolic BP reduction (B = –5.27; P < .001).

What portion of DarioHealth clients use its cardio-metabolic suite according to the announcement?

The company reported that 59% of its clients leverage the cardio-metabolic suite to manage hypertension.

What investor impact does the DRIO study imply for employers and payers?

The announcement says improved BP control could reduce downstream cardiovascular risks and related costs for employers, payers and health systems.

When were the JMIR Cardio findings about DarioHealth's BP outcomes released?

The findings were published and announced on December 4, 2025.